

Special Issue

Sensitization Strategies in Cancer Treatment

Message from the Guest Editor

Dear Colleagues, Due to high mortality rates and increasing incidence, cancer research efforts should focus on delineating the molecular basis of tumor resistance to current therapies, which will aid in designing novel strategies or improving the existing ones. Induction of apoptosis is the favored mode of action of most anti-neoplastic chemotherapeutics to eradicate tumors. To avoid apoptosis, tumors assume various mechanisms. For instance, natural apoptosis inhibitors, such as anti-apoptotic Bcl-2 and Inhibitors of Apoptosis (IAP) family members employ different mechanisms to protect tumors against apoptosis induced by anti-cancer agents. Drug-resistance is additionally strengthened by the appearance of the multi-drug resistance (MDR) phenotype following initial chemotherapy administration. This Special Issue will highlight the power of tumor sensitization to apoptosis, covering both basic and (pre)clinical aspects that advance our understanding and provide rational molecular basis for its utilization in clinical oncology.

Guest Editor

Dr. Ali R. Jazirehi

Department of Life Sciences, Los Angeles City College, Los Angeles, CA, USA

Deadline for manuscript submissions

closed (15 September 2018)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/11599

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)